[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"helicobacter-pylori\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:helicobacter-pylori":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,44,79,106,136,164,195,218,244,265,286,311],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100583073","study-of-the-esophageal-string-test-est-for-the-diagnosis-of-helicobacter-pylori-100583073",false,"NCT06871579","Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori","A Pilot Prospective Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Aged \\>=18 years\n* Diagnosed with H. pylori infection (by endoscopy, stool antigen, or urea breath testing)\n* Agreement to adhere to lifestyle considerations throughout study duration\n* Ability of participant to provide informed consent\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnancy or lactation\n* Use of antibiotics with activity against H. pylori within 4 weeks of enrollment\n* Inability to swallow pills\n* Biopsy-proven high grade dysplastic Barrett s esophagus, active peptic ulcer disease, recent (within 4 weeks) upper GI bleed, and\u002For history of Zollinger Ellison syndrome or gastric bypass surgery","ALL","18 Years","99 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nHelicobacter pylori is a bacterium that infects the lining of the stomach and intestines. It can cause peptic ulcers, cancers, and infections. Current methods of diagnosing H. pylori infections have limitations. Researchers want to test a new method of testing for H. pylori.\n\nObjective:\n\nTo compare the esophageal string test (EST) to standard tests for detecting H. pylori infection.\n\nEligibility:\n\nPeople aged 18 years or older with persistent H. pylori infection.\n\nDesign:\n\nParticipants will have 3 or 4 clinic visits over 2 to 4 months.\n\nScreening visit: Participants will have a physical exam. They will provide a stool sample.\n\nBaseline visit: Participants will have blood tests. Then they will have the EST: One end of a string will be taped to the outside of their cheek; the other end will be packed into a capsule. Participants will swallow the capsule, and the string will unwind down their throat into their stomach. The string will be left in for at least 1 hour. Then researchers will gently pull out the string. The fluids soaked into the string will be studied. Some participants will be prescribed antibiotics.\n\nFollow-up visit 1: Participants whose H. pylori infection was cured by the antibiotics may leave the study. Those who are still infected will have an endoscopy: A flexible tube will be inserted down the throat and into the stomach. It will take tissue samples from the stomach lining. These participants will then receive antibiotics again.\n\nFollow-up visit 2: The physical exam, blood test, and stool sample will be repeated.\n\n...",[27],"Helicobacter Pylori",[27,29,30],"Antibiotic resistance","DIAGNOSTIC TEST","RECRUITING","2026-06-24",{"date":34,"type":35},"2026-06-25","ACTUAL",{"date":37,"type":35},"2025-06-11",{"date":39,"type":21},"2027-01-30",{"name":41,"class":42},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100634280","phase-4-vonoprazan-based-versus-esomeprazole-based-triple-therapy-for-helicobacter-pylori-eradication-100634280","NCT07537634","Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication","Comparison Between Vonoprazan-Based Triple Therapy and Esomeprazole-Based Triple Therapy for Eradication of Helicobacter Pylori Infection: An Open-Label Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Dyspeptic patients with positive for both rapid urease test and stool antigen test\n3. Patients giving written informed consent\n\nExclusion Criteria:\n\n1. Treatment with a proton pump inhibitor, H2-receptor antagonist within the last 2 weeks, prior to the study\n2. Treatment with antibiotics or bismuth preparation within 4 weeks prior to the study\n3. Previous H. pylori eradication therapy\n4. Gastric or duodenal ulcer with current or recent bleeding on endoscopy\n5. Significant upper or lower gastrointestinal bleeding within 4 weeks\n6. Patients with regular intake of NSAIDs or steroids\n7. Surgery that might affect gastric acid secretion e.g., upper GI resection or vagotomy\n8. Known case of malignancy, including MALToma\n9. Advanced co-morbidities (e.g., CLD, CKD, cardio-respiratory failure, known thyroid disease)\n10. Chronic alcohol abuse, chronic illegal drug use, or drug addiction within the past 12 months\n11. Pregnant, lactating woman or intend to become pregnant within the study period\n12. History of hypersensitivity to vonoprazan, PPIs, amoxicillin, and\u002For levofloxacin\n13. On colchicine\n14. Subjects with abnormal laboratory test at the start of the screening period:\n\nS. creatinine \\> 2 mg\u002Fdl SGPT \\> 2 x Upper limit of normal",{"count":52,"type":21},80,[54],"PHASE4","The goal of this clinical trial is to compare the efficacy and safety of vonoprazan-based levofloxacin-containing triple therapy with esomeprazole-based levofloxacin-containing triple therapy for eradication of Helicobacter pylori infection in adults with dyspepsia.\n\nThe main questions it aims to answer are whether vonoprazan-based triple therapy achieves a higher eradication rate of H. pylori, whether it provides greater improvement in dyspeptic symptoms, and what adverse effects are associated with each regimen.\n\nResearchers will compare the two treatment regimens to determine which is more effective for H. pylori eradication.\n\nParticipants with confirmed H. pylori infection will be randomly assigned to receive either vonoprazan-based or esomeprazole-based triple therapy for 14 days.\n\nFour weeks after completion of therapy, participants will undergo repeat stool antigen testing to assess eradication.\n\nDrug compliance, adverse effects, and dyspeptic symptom scores will be recorded during follow-up.\n\nParticipants with endoscopic mucosal lesions at baseline will undergo follow-up endoscopy for reassessment.",[57,58,59,27,60],"Helicobacter Pylori Infection","Dyspepsia","Peptic Ulcer Disease","H Pylori",[62,63,64,65,66,67,58],"Helicobacter pylori","Helicobacter pylori eradication","Vonoprazan","Esomeprazole","Levofloxacin","Triple therapy","2026-04-18",{"date":70,"type":35},"2026-04-22",{"date":72,"type":21},"2026-04-15",{"date":74,"type":21},"2026-08-14",{"name":76,"class":77},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","OTHER",2,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":43},"100610785","phase-4-7-day-vonoprazan-high-dose-amoxicillin-and-bismuth-therapy-100610785","NCT07232095","7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy","7-Day Vonoprazan-High-Dose Amoxicillin-Bismuth Therapy for First-Line Eradication of Helicobacter Pylori: A Multicenter Randomized Controlled Trial","JSHERO4","Inclusion Criteria:\n\n1. Aged 18 to 70 years, regardless of sex.\n2. Helicobacter pylori infection confirmed by ¹³C or ¹⁴C urea breath test within 1 month before enrollment.\n3. Chronic gastritis with H. pylori infection confirmed by endoscopy within 3 months, meeting the indications for eradication therapy in the Sixth National Consensus Report on the Management of Helicobacter pylori Infection (China), and willing to receive eradication treatment.\n4. No prior H. pylori eradication therapy.\n5. Written informed consent before participation.\n\nExclusion Criteria:\n\n1. Known allergy or hypersensitivity to any study medication (vonoprazan, amoxicillin, or bismuth).\n2. Use of potassium-competitive acid blockers (P-CABs), proton pump inhibitors (PPIs), H₂ receptor antagonists, antibiotics, bismuth preparations, or probiotics within 4 weeks before enrollment.\n3. Pregnant or lactating women.\n4. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or anticoagulants during the study period.\n5. Presence of serious comorbid conditions that may interfere with study evaluation, including significant cardiac, pulmonary, hepatic, renal, metabolic, or psychiatric disorders, or malignancy.\n6. History of gastric or esophageal surgery.\n7. Any condition or factor that may affect compliance or make it difficult for the subject to complete follow-up as required.","70 Years",{"count":89,"type":21},316,[54],"The 2024 American College of Gastroenterology (ACG) Clinical Guideline recommends a 14-day vonoprazan-amoxicillin (VA) regimen, consisting of vonoprazan 20 mg twice daily with amoxicillin 1000 mg three times daily, as a first-line treatment for Helicobacter pylori (H. pylori) infection.\n\nOur previous study on regimen optimization showed that vonoprazan 20 mg twice daily combined with amoxicillin 1 g three times daily or 750 mg four times daily for 10 days achieved satisfactory eradication rates exceeding 90%, with no significant difference between dosing frequencies. However, when the treatment duration was shortened to 7 days, both dosing schedules failed to reach satisfactory eradication rates, indicating a need for further optimization.\n\nBismuth has antibacterial and synergistic properties, such as disrupting bacterial membranes, suppressing protein synthesis, and reducing virulence factor expression. It may enhance the efficacy of antibiotics. Therefore, this study evaluated the efficacy and safety of a 7-day vonoprazan-high-dose amoxicillin-bismuth (VAB-7) regimen as a first-line treatment for H. pylori infection.\n\nEligible participants in this study will be randomly assigned to one of the following treatment groups based on a pre-generated randomization sequence:\n\nControl Group: Vonoprazan combined with high-dose amoxicillin dual therapy for 14 days (VA-14): Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily.\n\nExperimental Group: Vonoprazan combined with high-dose amoxicillin and bismuth therapy for 7 days (VAB-7): Vonoprazan 20mg twice daily + Amoxicillin 1g three times daily+Bismuth 220mg twice daily.",[27],[27,64,94,95,96],"Amoxicillin","Bismuth","Eradication","2026-04-07",{"date":99,"type":35},"2026-04-08",{"date":101,"type":35},"2026-01-08",{"date":103,"type":21},"2027-06-30",{"name":105,"class":77},"The First Affiliated Hospital with Nanjing Medical University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100600963","phase-3-personalized-vs-standard-of-care-treatment-for-helicobacter-pylori-eradication-among-veterans-100600963","NCT07104318","Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","Randomized Clinical Trial of Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans: \"VA Eradicate HP\"","VA EradicateHP","Inclusion Criteria:\n\n* Adult Veterans ages 18 years or older, irrespective of sex\u002Fgender (male, female, non-binary, other preferred classification).\n* Treatment-naïve patients with active H. pylori infection as determined by a positive H. pylori stool antigen (HPsAg), gastric biopsy, or urease breath test. All individuals who test positive based on a non-HPsAg modality will need to have a positive HPsAg documented within 4 weeks of enrollment to be considered eligible.\n* Subjects who can understand and sign written informed consent.\n\nExclusion Criteria:\n\nThe investigators will exclude individuals with:\n\n* Severe gastrointestinal (GI) symptoms that limit the ability to tolerate study medications. Note: The presence of symptoms or GI diagnoses such as irritable bowel syndrome or gastroesophageal reflux does not impact H. pylori eradication and will not be exclusion criteria unless deemed that symptom severity will impact adherence.\n* Conditions where urgent H. pylori treatment is recommended (i.e., active peptic ulcer disease (PUD) complicated by bleeding, perforation, or obstruction; gastric neoplasia including MALT lymphoma). Active PUD is defined as having a gastric or duodenal ulcer confirmed on an upper endoscopic procedure in the 4 weeks prior to eligibility determination.\n* Inability to be safely off of PPI for two weeks to allow for accurate post-treatment HPsAg testing. These conditions include Barrett's esophagus with dysplasia, active PUD, severe esophagitis defined as Los Angeles Classification C or D esophagitis.\n* Allergy or severe intolerance\u002Fcontraindication to any of the treatment components. Note: In patients with penicillin allergy, metronidazole is often substituted for amoxicillin in PPI clarithromycin triple therapy. However, this alternative regimen demonstrates higher failure rates vs. PPI-clarithromycin triple therapy with amoxicillin among Veterans and thus the investigators elected to exclude patients with penicillin allergy.\n* Severe medical comorbidity that is a threat to life. This includes, but is not limited to, coronary artery disease with myocardial infarction or equivalent (e.g., cerebrovascular event) within 12 months, unstable angina or congestive heart failure, cardiac or vascular stent placement within 12 months, chronic obstructive pulmonary disease requiring home oxygen, decompensated cirrhosis, end-stage renal disease, other diseases that limit life expectancy to less than 5 years.\n* Any prior history of upper gastrointestinal surgery or gastric cancer diagnosis.\n* Past liver transplant or allogenic bone marrow transplant, given that pharmacogenomic testing is inaccurate for these patients.\n* Any history of recurrent Clostridioides difficile infection (CDI), defined as an episode of CDI occurring within 8 weeks of a previous CDI episode; or any episode of CDI within the preceding 12 months.\n* Evidence of any overt gastrointestinal bleeding.\n* History of photosensitive reactions to any medications.\n* Women who are pregnant, lactating, or of childbearing age without reliable contraception (Note: all women of childbearing age will be asked to submit a urine pregnancy test prior to enrollment).\n* Prior CYP2C19 or PHASER testing or HP antimicrobial susceptibility profiling before enrollment.",{"count":115,"type":21},360,[117],"PHASE3","The primary objective of this study is to compare the Helicobacter pylori (H. pylori) eradication rate following empiric bismuth-based quadruple therapy (BQT) versus a personalized H. pylori treatment strategy in treatment-naïve Veterans with confirmed H. pylori infection.\n\nThis study is an eight-week, parallel two-arm, double-blinded, prospective, single-site randomized clinical trial designed to test the hypothesis that personalized H. pylori therapy achieves higher eradication rates compared to the standard empiric BQT regimen. Secondary outcomes include comparisons of treatment adherence, tolerability, and the incidence of treatment-related side effects and adverse events between the two groups. A total of 360 treatment-naïve Veterans with active H. pylori infection, confirmed by a positive H. pylori stool antigen test (HPsAg), will be enrolled, randomized, and analyzed at the VA San Diego Healthcare System (VASDHS). Participants who meet eligibility criteria and provide informed consent will be randomized in a 1:1 ratio to receive either a 14-day personalized H. pylori treatment regimen (n=180) or a standard 14-day empiric BQT regimen (n=180).\n\nParticipants randomized to personalized therapy will receive H. pylori treatment that incorporates 1) standard or optimized proton pump inhibitor (PPI) dosing according to participants' CYP2C19 metabolizer phenotype, and 2) tailored antibiotics according to participants' noninvasive (stool) H. pylori antibiotic susceptibility testing (AST). All participants will complete a baseline questionnaire and provide pre-treatment stool and blood samples for H. pylori AST and serum CYP2C19 testing, respectively. Follow-up will include brief telephone interviews during week 1 and week 2 of treatment and again two weeks post-treatment to assess adherence and monitor for adverse events. Cure will be assessed using a post-treatment stool antigen test (HPsAg) at week 8 (four weeks after completing therapy).",[27],[62,121,122,123,124,125],"H. pylori","Randomized Intervention Study","CYP2C19","antibiotic susceptibility","personalized treatment","NOT_YET_RECRUITING","2026-04-01",{"date":97,"type":35},{"date":130,"type":21},"2026-07-01",{"date":132,"type":21},"2030-06-30",{"name":134,"class":135},"VA Office of Research and Development","FED",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":43},"100435402","prevalence-of-helicobacter-pylori-infection-and-gastric-cancer-in-the-west-indies-100435402","NCT04949737","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies","Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies: Helico-MQ Interventional Study","Hélico-MQ","Inclusion Criteria:\n\n1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer\n2. Patient having read the information note and having signed the consent to participate in the study\n3. Patient with social security coverage\n\nExclusion Criteria:\n\n1. Refusal to participate\n2. Patient who could not answer the questionnaires\n3. Patient not affiliated to a social security system\n4. Patient not fluent in French\n5. Patient under legal protection (legal protection, guardianship, curators, etc.)",{"count":145,"type":21},112,"OBSERVATIONAL","Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.",[149,150,27],"Stomach Neoplasms","Gastric Neoplasms",[27,152,153,154],"Gastric cancer","Prevalence","French West-Indies","2026-03-26",{"date":157,"type":35},"2026-03-31",{"date":159,"type":35},"2025-10-09",{"date":161,"type":21},"2028-12",{"name":163,"class":77},"University Hospital Center of Martinique",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":175,"conditions":176,"keywords":180,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":43},"100556749","h-pylori-eradication-with-argon-plasma-during-endoscopy-100556749","NCT06529159","H. Pylori Eradication With Argon Plasma During Endoscopy","H. Pylori Eradication With Argon Plasma During Endoscopy (HEAPE)","HEAPE","Inclusion Criteria:\n\n1. Subjects must be 18 years or older\n2. Confirmed untreated H. pylori infection\n3. Able to understand and sign informed consent\n4. Available to return for all routine follow-up study visits\n5. Patients should have upper endoscopy scheduled according to latest guidelines, e.g., as a part of their diagnostic work-up of HP positive test, regardless of their decision to participate in the study.\n\nExclusion Criteria:\n\n1. Patients actively undergoing H.pylori eradication therapy treatment with antibiotics or proton pump inhibitors (PPIs) two weeks prior to the HEAPE procedure.\n2. Pregnancy or puerperium\n3. Severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)\n4. Lactation\n5. An inability to provide informed consent\n6. Any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study.\n7. Hernias \u002F aspiration risk",{"count":173,"type":21},20,[24],"The objective of the study is to investigate the efficacy and safety of an argon plasma-based therapy - HEAPE - in treating H. pylori infections during endoscopic procedures. By filling the stomach with sodium chloride solution that is treated with APC (PAL), the Investigators hypothesize a significant reduction in H. pylori. The use of PAL instead of direct application of APC allows for a broader and more homogeneous application throughout the stomach and a faster procedure time, as the fluid bypasses the thermal effects typically associated with higher electrical power settings and focuses on the bactericidal action of PAL. It is a procedure that does not involve thermal ablation of the stomach lining. Thus, side effects should be expected to be as low as possible.\n\nTwo different PAL generation modalities will be compared in this study:\n\n1. HEAPE direct: This modality is the direct generation of PAL in the stomach. The stomach is filled with sodium chloride solution which is then treated with APC. With HEAPE direct a potential decrease of reactive species is avoided, as the treatment happens directly at the intended location in the H. pylori infected stomach.\n2. Pre-HEAPE: This modality features the treatment of sodium chloride with APC outside of the patient in a sterile container. After the APC treatment, the generated PAL is administered into the stomach with a syringe through the working channel of the endoscope. Pre-HEAPE allows an easier handling of the APC probe as the treatment of the sodium chloride solution can be done without an endoscope.\n\nTo evaluate the immediate effect of this novel treatment approach the metabolic activity of H. pylori will be assessed using a urea breath test (UBT) before and after treatment. A reduction in H. pylori levels can be detected by a reduction in urease activity in the breath test.\n\nAfter the HEAPE procedure, patients are treated with antibiotics (best practice) as they would be under normal circumstances. Four weeks after treatment, another UBT is performed to determine if H. pylori has been eradicated or if additional antibiotic treatment is indicated.\n\nThis two-arm, randomized, pilot, single-center, prospective clinical study is designed to evaluate the safety, tolerability and proof of concept that PAL has the ability to eradicate or reduce the bacterial load of H. pylori in humans.",[57,27,177,178,179],"Helicobacter Pylori Gastrointestinal Tract Infection","H. Pylori Infection","H. Pylori Gastrointestinal Disease",[181,182,183,184,185],"Urea Breath Test","Argon Plasma Coagulation (APC)","Endoscopy","Plasma Activated Liquid (PAL)","Plasma Medicine","2026-02-26",{"date":188,"type":35},"2026-03-02",{"date":190,"type":35},"2025-07-08",{"date":192,"type":21},"2027-12",{"name":194,"class":77},"Christopher C. Thompson, MD, MSc",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":202,"sex":16,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":43},"100588621","prospective-gastric-cancer-screening-using-helicobacter-pylori-high-risk-single-nucleotide-polymorphism-detection-100588621","NCT06943781","Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection","Research on the Application of Fecal Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection in the Early Diagnosis and Screening of Gastric Cancer","Inclusion Criteria:\n\n1. Age ≥40 years, male or female.\n2. No contraindications to endoscopy and able to cooperate with endoscopy.\n3. Patients must be able to fully understand the informed consent form and be able to sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. A history of diagnosed gastric cancer or other malignant tumors of the digestive tract.\n2. Comorbid severe underlying conditions (e.g., severe cardiopulmonary insufficiency, liver or renal failure, etc.) that are likely to result in a short life expectancy or render long-term follow-up impractical.\n3. Severe mental illness or incapacity to participate in the study due to lack of civil behavior.\n4. Pregnant or breastfeeding women.\n5. Other conditions that the investigator deems inappropriate for participation in the study.",true,"40 Years",{"count":205,"type":21},15000,"This is a prospective study designed to compare the performance of fecal H. pylori gastric cancer susceptibility analysis and the gastric cancer risk questionnaire for the early detection of gastric cancer. The primary objective is to assess whether each method, individually or in combination, can facilitate earlier diagnosis of gastric cancer. All participants will undergo fecal H. pylori gastric cancer susceptibility testing and complete the gastric cancer risk questionnaire.",[208,27],"Gastric Adenocarcinoma","2026-02-23",{"date":211,"type":35},"2026-02-25",{"date":213,"type":35},"2025-07-01",{"date":215,"type":21},"2027-12-31",{"name":217,"class":77},"Fudan University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":43},"100612466","distribution-characteristics-of-helicobacter-pylori-100612466","NCT07253948","Distribution Characteristics of Helicobacter Pylori","Distribution Characteristics of Helicobacter Pylori in Different Gastritis and Early Gastric Cancer States Using Immunohistochemical Staining","Inclusion Criteria:\n\n* age 18-80 years\n* received H. pylori immunohistochemical testing at our center and tested positive.\n\nExclusion Criteria:\n\n* biopsies not collected from both the greater and lesser curvatures of the gastric antrum and body\n* history of stomach surgery\n* suspected autoimmune gastritis under endoscopy\n* liver cirrhosis\n* severe comorbidities such as advanced cancer or renal failure\n* advanced gastric cancer or gastric lymphoma","80 Years",{"count":227,"type":21},231,"This study aimed to analyze the distribution characteristics of Helicobacter pylori（H. pylori） in varying stages of atrophic gastritis and early gastric cancer using immunohistochemical staining, with the goal of providing guidance for the early screening of gastric cancer.\n\nA retrospective analysis was conducted on gastric biopsy cases that underwent H. pylori immunohistochemical staining at our center from March 1, 2023, to August 15, 2025. Cases were classified into non-atrophic and atrophic groups based on the presence or absence of gastric atrophy. All cases were further divided into non-open and open atrophy groups and additionally into early gastric cancer and non-cancer groups. The distribution of H. pylori across subgroups was compared, and multivariate analyses were performed to identify risk factors associated with the development of early gastric cancer.",[27,230],"Early Gastric Cancer",[62,232,233,234],"Immunohistochemical staining","Atrophic gastritis","Early gastric cancer screening","2025-11-26",{"date":237,"type":35},"2025-11-28",{"date":239,"type":35},"2025-10-22",{"date":241,"type":21},"2025-12-31",{"name":243,"class":77},"Jilin University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":43},"100602324","phase-4-efficacy-and-safety-of-keverprazan-amoxicillin-dual-therapy-for-helicobacter-pylori-first-line-treatment-100602324","NCT07122024","Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment","Inclusion Criteria\n\n1. Adult patients aged 18 to 65 years old, regardless of gender;\n2. H. pylori positive, diagnosed a 13C-urea breath test (13C-UBT), ¹⁴C-urea breath test (¹⁴C-UBT), H\\&E staining or bacterial culture;\n3. No previous history of H. pylori eradication therapy;\n4. Subjects able to independently complete the recording of the subject diary card;\n5. Subjects who fully understand the trial content, voluntarily participate in the trial, can complete the trial process, and sign the informed consent form.\n\nExclusion Criteria\n\n1. Use of acid-suppressing drugs such as proton pump inhibitors (PPIs), potassium-competitive acid blocker (P-CAB), H2 receptor antagonists, etc., within 2 weeks before enrollment, or use of antibiotics within 4 weeks before enrollment;\n2. Active peptic ulcer with complications such as bleeding, perforation, obstruction, canceration, etc.;\n3. Previous history of esophageal or gastric surgery;\n4. Severe systemic diseases, including diseases of major organs dysfunction such as (cardiac, pulmonary, cerebral), hepatic or renal impairment, malignant neoplasms , or other diseases;\n5. Participants with allergies or hypersensitivity to keverprazan, rabeprazole, amoxicillin, clarithromycin, bismuth agents, including its excipients (such as mannitol, microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, etc.);\n6. Female participants who are pregnant, breastfeeding;\n7. Long-term alcohol abuse or any other conditions that increase the risk of treatment-related adverse events;\n8. Participation in other studies within the past 3 months, inability to clearly express oneself, or inability to cooperate with investigators;\n9. Deemed unsuitable for participation in the study by the investigator for any other reason.","65 Years",{"count":252,"type":21},414,[54],"This is an open-label, randomized controlled study. The study plans to enroll 414 subjects with Helicobacter pylori infection, who will be randomly assigned to the experimental group (Keverprazan dual therapy for 10 days or Keverprazan dual therapy for 14 days) or the control group (Rabeprazole quadruple therapy for 14 days) at a ratio of 1:1:1.",[27],"2025-08-09",{"date":258,"type":35},"2025-08-14",{"date":260,"type":35},"2024-02-19",{"date":262,"type":21},"2025-12-30",{"name":264,"class":77},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":202,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":273,"studyType":146,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":284,"locationsCount":78},"100443403","helicobacter-pylori-atrophic-gastritis-and-intestinal-metaplasia-registry-and-prospective-study-100443403","NCT05053945","Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study","Inclusion Criteria:\n\n* Adults \\>= 18 years of age\n* Written informed consent obtained\n* Diagnosed with current or past H. pylori infection,\n* Histologically proven atrophic gastritis (body and\u002For antrum of stomach), intestinal metaplasia (complete and incomplete), dysplasia (any grade) and\u002For gastric cancer (post- treatment)\n\nExclusion Criteria:\n\n* Co-morbid illness that prohibit endoscopic surveillance\n* Declines for study questionnaire, biobanking of specimens and\u002For regular review per study protocol",{"count":272,"type":21},260,"3 Years","Since much is unknown about factors that lead to progression of the pre-neoplastic lesions and cancer. In addition, there is ongoing debate on the optimal surveillance intervals and techniques. To solve these important clinical questions, the establishment of a registry for a longitudinal study is planned.",[27,276,277],"Atrophic Gastritis","Intestinal Metaplasia","2024-08-28",{"date":280,"type":35},"2024-08-29",{"date":282,"type":35},"2020-05-15",{"date":241,"type":21},{"name":285,"class":77},"Chinese University of Hong Kong",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":202,"sex":16,"minAge":273,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":22,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":310},"100460509","phase-3-pyloplus-urea-breath-test-system-pediatric-safety-and-efficacy-study-100460509","NCT05276557","PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study","Inclusion Criteria:\n\n* Male or female age 3-17 at the time of visit\n* Subject\u002FLegal guardian (and subject when relevant) is willing to sing the Informed Consent\u002FAssent Form\n* Naive to H. pylori treatment in the past 4 weeks\n\nExclusion Criteria:\n\n* Pregnant and\u002For lactating women\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient of the quality of data\n* Participation in other interventional trials\n* Allergy to test substrates\n* Antibiotics taken within 4 weeks of the testing\n* Study subjects shall not consume the following items at least 1 hour prior to the PPUBT test: Mouthwash, Chewing Gum, Carbonated Beverages, Cigarette Smoke, Acetone (to simulate the effect of ketone production that may result from some diets), Alcohol, Food\n* Children 12 years and older - to be excluded after a written notification from the sponsor is received at the site that the limit of (approx.) 1\u002F3 of the sample size was achieved for this group","17 Years",{"count":294,"type":21},40,[117],"This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample.\n\nCenters will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System.\n\nTreating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician.\n\nTotal duration of study is anticipated to be approximately 6 months.",[27,298,299],"Safety","Efficacy","2023-05-03",{"date":302,"type":35},"2023-05-06",{"date":304,"type":35},"2022-11-17",{"date":306,"type":21},"2023-06",{"name":308,"class":309},"ARJ Medical, Inc.","INDUSTRY",3,{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":4,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":43},"100280652","phase-4-the-influence-of-helicobacter-pylori-eradication-on-gastric-pathology-a-long-term-prospective-cohort-study-100280652","NCT02933229","The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with H. pylori infection;\n* Aged 18-65 years.\n\nExclusion Criteria:\n\n* Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;\n* Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function;\n* Pregnancy or breastfeeding;\n* Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.","60 Years",{"count":319,"type":21},300,[54],"Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies",[27,323,324],"the Operative Link on Gastric Intestinal Metaplasia","Operative Link on Gastric Intestinal Assessment","2016-10-12",{"date":327,"type":21},"2016-10-14",{"date":329,"type":4},"2016-10",{"date":331,"type":21},"2031-10",{"name":333,"class":77},"Shandong University"]